Patent Portfolio
GlycoNex's glycan-directed oncology programs are protected by 36 granted patents across multiple jurisdictions, plus published and pending applications. Granted and published patent numbers are listed below for partner due diligence.
GNX102 / GNX1021 Antibody Family
The anti-branched Lewis B/Y therapeutic antibody behind lead ADC GNX1021, together with its antibody-drug conjugate composition and method-of-use applications.
Granted patents (9)
| Jurisdiction | Patent No. |
|---|---|
| US | US11440967B2 |
| US | US11643471B2 |
| CN | CN112533948B |
| JP | JP7696404B2 |
| KR | 10-2480815 |
| TW | I842712 |
| MX | 424537 |
| RU | 2803097 |
| IL | 279109 |
A further 10 applications are pending, including in Australia, Brazil, Canada, Europe (EPO), India, Singapore, and the United States.
GNX8
An anti-extended type I glycosphingolipid antibody covered by 27 granted patents worldwide; patents held by GlycoNex and licensed to Otsuka Pharmaceutical since 2009.
Representative grants (6 of 27)
| Jurisdiction | Patent No. |
|---|---|
| US | US 8163497 B2 |
| EP | EP 2324060 B1 |
| JP | JP 5611210 B2 |
| TW | TW I433684 B |
| CN | CN 102282172 B |
| KR | KR 101442323 B1 |
GNX201-ADC (Pro-Antibody)
Published patent applications for the pro-antibody ADC program; status is published, pending grant.
Published applications (published, pending grant)
| Authority | Publication No. | Status |
|---|---|---|
| PCT (WIPO) | WO 2026/102136 | Published |
| United States | US 2026/0125489 | Published (pre-grant) |
An additional application is pending in Taiwan. These are published patent applications (pending grant), not granted patents.